Conclusions
The combination of Danlou tablets and aspirin significantly improves clinical symptoms in CHD patients with phlegm and blood stasis syndrome, reduces serum sPLA2, LP-PLA2, and ox-LDL levels, and inhibits inflammatory responses, suggesting this combination could provide a beneficial adjunctive therapy for managing CHD in these patients. This study serves as a reference for further research on Danlou tablets' role in CHD.
Methods
This study is a retrospective study, a total of 120 patients with phlegm and blood stasis syndrome with CHD were randomly assigned to either a control group (aspirin, 100 mg, once daily) or an observation group (Danlou tablets, 1.5 g, three times daily; aspirin, 100 mg, once daily) at a 1:1 ratio. Treatment was administered for 28 consecutive days. Pre- and post-treatment assessments included lipid profiles, hemorheology, inflammatory markers, serum phospholipase A2 (sPLA2), lipoprotein-associated phospholipase 2 (LP-PLA2), oxidized low-density lipoprotein (ox-LDL), monocyte chemotactic protein-1 (MCP-1), clinical efficacy, adverse events, and changes in TCM syndrome scores.
Results
After 1 month of treatment, the observation group showed a significantly higher overall clinical efficacy rate (P = 0.038) compared to the control group. Post-treatment levels of sPLA2, LP-PLA2, ox-LDL, and MCP-1 decreased in both groups, with significantly lower levels in the observation group (P = 0.001, P = 0.013, P = 0.015). Additionally, reductions in small dense low-density lipoprotein cholesterol (sdLDL-C), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), fibrinogen, erythrocyte volume, tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) were significantly greater in the observation group than in the control group (P = 0.023, P = 0.023, P = 0.014, P = 0.012, P = 0.032, P = 0.019, P = 0.030). Conclusions: The combination of Danlou tablets and aspirin significantly improves clinical symptoms in CHD patients with phlegm and blood stasis syndrome, reduces serum sPLA2, LP-PLA2, and ox-LDL levels, and inhibits inflammatory responses, suggesting this combination could provide a beneficial adjunctive therapy for managing CHD in these patients. This study serves as a reference for further research on Danlou tablets' role in CHD.